B cell maturation antigen
Target id: 1889
Nomenclature: B cell maturation antigen
Abbreviated Name: BCMA
Systematic Nomenclature: TNFRSF17
Contents:
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 184 | 16p13.13 | TNFRSF17 | TNF receptor superfamily member 17 | |
| Mouse | 1 | 185 | 16 A1 | Tnfrsf17 | tumor necrosis factor receptor superfamily, member 17 | |
| Rat | - | - | Tnfrsf17 | TNF receptor superfamily member 17 | ||
| Previous and Unofficial Names |
| tumor necrosis factor receptor superfamily, member 17 | BCM | CD269 | TNFRSF13a | tumor necrosis factor receptor superfamily |
| Database Links |
|
| Alphafold | Q02223 (Hs), O88472 (Mm) |
| ChEMBL Target | CHEMBL4523587 (Hs), CHEMBL1250345 (Mm) |
| Ensembl Gene | ENSG00000048462 (Hs), ENSMUSG00000022496 (Mm), ENSRNOG00000021987 (Rn) |
| Entrez Gene | 608 (Hs), 21935 (Mm), 287034 (Rn) |
| Human Protein Atlas | ENSG00000048462 (Hs) |
| KEGG Gene | hsa:608 (Hs), mmu:21935 (Mm), rno:287034 (Rn) |
| OMIM | 109545 (Hs) |
| Pharos | Q02223 (Hs) |
| UniProtKB | Q02223 (Hs), O88472 (Mm) |
| Wikipedia | TNFRSF17 (Hs) |
| Natural/Endogenous Ligands |
| APRIL {Sp: Human} |
| BAFF {Sp: Human} |
| Adaptor proteins (Human) |
| TRAF1, TRAF2, TRAF3, TRAF5, TRAF6 |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| B-cell maturation antigen (BCMA) is a cell surface receptor for B-cell activating factor (BAFF). It interacts with various TRAF family adaptor proteins to modulate cell survival and proliferation, via NF-κB and MAPK8/JNK signal transduction pathways. BCMA is highly plasma cell-selective for malignant plasma cells from multiple myeloma (MM) patients, and is being investigated as a target for therapies to tackle relapsed/refractory MM [2,4]. Novel BCMA-directed therapeutic agents in early stage development for MM include monoclonal antibodies and CAR-T cells [3,5,7]. The antibody-drug conjugate belantamab mafodotin (GSK2857916) [6] is one of the early phase anti-BCMA clinical candidates that is being evaluated in patients with relapsed/refractory MM. |
| Immuno Process Associations | ||
|
||
|
||
|
||
|
References
1. Algate P, Clegg SJ, Craigen JL, Hamblim PA, Lewis AP, Mayes P, Parmar RS, WattamTAK. (2016) B cell maturation antigen (BCMA) binding proteins. Patent number: US9273141B2. Assignee: Glaxo Group Ltd. Priority date: 27/05/2011. Publication date: 01/03/2016.
2. Hengeveld PJ, Kersten MJ. (2015) B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J, 5: e282. [PMID:25723853]
3. Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. (2017) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia, 31 (8): 1743-1751. [PMID:28025583]
4. Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM et al.. (2016) Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol, 174 (6): 911-22. [PMID:27313079]
5. Podar K, Pecherstorfer M. (2017) Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother, 18 (11): 1061-1079. [PMID:28604120]
6. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W et al.. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 123 (20): 3128-38. [PMID:24569262]
7. (2017) Sending CAR T Cells After Multiple Myeloma. Cancer Discov, 7 (8): OF9. [PMID:28588060]
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License